Literature DB >> 2601882

Comparison of the effects of intracerebrally administered MPP+ (1-methyl-4-phenylpyridinium) in three species: microdialysis of dopamine and metabolites in mouse, rat and monkey striatum.

H Rollema1, G M Alexander, J R Grothusen, F F Matos, N Castagnoli.   

Abstract

Intracerebral microdialysis in 3 awake species allowed the measurement of the basal output of dopamine (DA), dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and 5-hydroxyindole-acetic acid (5-HIAA) from rat and mouse striatum and monkey caudate in vivo. The DOPAC/HVA ratios in dialysates from mouse and rat striatum were about 1 and 2 respectively, but only 0.09 in monkey caudate dialysates. The extracellular levels of the metabolites correlated well with reported tissue levels, while extracellular DA levels were 3 orders of magnitude lower than tissue concentrations. The effects of the intracerebrally administered dopaminergic neurotoxin 1-methyl-4-phenylpyridinium (MPP+) were essentially similar in the 3 species. In all cases an immediate, massive release of DA was accompanied by a pronounced decrease in the output of the metabolites. Basal DA release was no longer detectable 5-12 h after MPP+ administration and a second MPP+ perfusion failed to increase the release of DA.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2601882     DOI: 10.1016/0304-3940(89)90176-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  3 in total

1.  Overview of microdialysis.

Authors:  T S Shippenberg; A C Thompson
Journal:  Curr Protoc Neurosci       Date:  2001-05

2.  Overview of brain microdialysis.

Authors:  Vladimir I Chefer; Alexis C Thompson; Agustin Zapata; Toni S Shippenberg
Journal:  Curr Protoc Neurosci       Date:  2009-04

Review 3.  Neonatal 6-hydroxydopamine lesioning of rats and dopaminergic neurotoxicity: proposed animal model of Parkinson's disease.

Authors:  Richard M Kostrzewa
Journal:  J Neural Transm (Vienna)       Date:  2022-03-12       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.